论文部分内容阅读
目的探讨表皮生长因子受体(EGFR)及细胞角蛋白5/6(CK5/6)在乳腺浸润性导管癌中的表达,为乳腺癌的个体化治疗提供依据。方法选择2012年1月1日-8月31日在新疆医科大学附属肿瘤医院手术且术后病理诊断乳腺浸润性导管癌病例267例(汉族203例,维吾尔族64例),均有完整病理资料(包含ER、PR、HER2、Ki-67、EGFR、CK5/6免疫组化结果),对EGFR、CK5/6在乳腺癌组织中的表达进行分析。结果 (1)EG-FR、CK5/6在乳腺浸润性导管癌中的表达率分别为27.3%(73/267)、21.3%(57/267),维吾尔族和汉族乳腺癌中EGFR、CK5/6表达差异无统计学意义。(2)EGFR、CK5/6表达与年龄、肿块大小、TNM分期、淋巴结转移无相关性(P>0.05)。(3)EGFR在组织学分级Ⅲ级中的表达率高于Ⅱ级,CK5/6在病理组织学分级Ⅲ级中的表达率高于Ⅰ级、Ⅱ级(P<0.05)。(4)EGFR在增殖指数(Ki-67)(++)组表达高于(-)、(+)组,CK5/6表达率随Ki-67升高而逐渐升高(P<0.05)。(5)EGFR、CK5/6共同表达率(即同时阳性表达或阴性表达)为77.5%。(6)EGFR、CK5/6在三阴性乳腺癌(triple-negative breast cancer TNBC)中表达率高于非三阴性乳腺癌(non-triple-negativebreast cancer NTNBC)。结论 EGFR、CK5/6在组织学分级较高组、Ki-67阳性组、TNBC表达率较高;EGFR、CK5/6具有共表达性;EGFR在TNBC高表达为其EGFR靶向治疗提供依据。
Objective To investigate the expression of epidermal growth factor receptor (EGFR) and cytokeratin 5/6 (CK5 / 6) in invasive ductal carcinoma of breast and to provide basis for individualized treatment of breast cancer. Methods From January 1, 2012 to August 31, 2012, 267 cases of invasive ductal carcinoma of the breast (203 cases of Han and 64 cases of Uygur) underwent surgery and postoperative pathological diagnosis of tumor at the Affiliated Tumor Hospital of Xinjiang Medical University. All of them had complete pathological data (Including ER, PR, HER2, Ki-67, EGFR, CK5 / 6 immunohistochemistry results), the expression of EGFR and CK5 / 6 in breast cancer tissues were analyzed. Results (1) The expression rates of EG-FR and CK5 / 6 in breast invasive ductal carcinomas were 27.3% (73/267) and 21.3% (57/267), respectively. The expressions of EGFR and CK5 / 6 expression difference was not statistically significant. (2) The expression of EGFR and CK5 / 6 had no correlation with age, tumor size, TNM stage and lymph node metastasis (P> 0.05). (3) The expression rate of EGFR in histological grade Ⅲ was higher than that in grade Ⅱ. The expression rate of CK5 / 6 in pathological grade Ⅲ was higher than that in grade Ⅰ and Ⅱ (P <0.05). (4) The expression of EGFR in the proliferation index (+) group was higher than that in the (+) and (+) groups, and the expression rate of CK5 / 6 increased gradually with the increase of Ki-67 (P <0.05). (5) The rates of EGFR and CK5 / 6 co-expression (ie, positive or negative expression at the same time) were 77.5%. (6) The expression rates of EGFR and CK5 / 6 in triple-negative breast cancer TNBC were higher than those in non-triple-negativebreast cancer NTNBC. Conclusions EGFR and CK5 / 6 are highly expressed in histological grade, Ki-67 positive group and TNBC are highly expressed. EGFR and CK5 / 6 are co-expressed. The high expression of EGFR in TNBC provides the basis for EGFR targeted therapy.